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Blastic natural killer (NK)-cell lymphoma is a clinically aggressive hemato-
logic neoplasm with a high incidence of cutaneous involvement. We report 
a 19-year-old man who presented with asymptomatic, erythematous, 
infiltrated bean plaques and nodules of various sizes, scattered over the 
face, trunk and extremities. A skin biopsy specimen revealed diffuse der-
mal infiltration of medium-sized pleomorphic cells with a blastic appear-
ance. Immunohistochemical studies showed that the tumor cells were 
positive for CD56, CD43, CD123, and terminal deoxynucleotidyl trans-
ferase (TdT). The neoplastic cells were negative for B-cell, T-cell, and 
myeloid cell markers. In situ hybridization for Epstein-Barr virus encoded 
RNA (EBER) gave a negative result. Flow cytometric analysis of bone mar-
row aspirate demonstrated a CD56 positive population of blastic cells. 
A diagnosis of blastic NK-cell lymphoma was made and the skin lesions 
regressed after treatment with L-asparaginase-based chemotherapy (L-
asparaginase, cyclophosphamide, etoposide). The skin lesions regressed 
after two sessions of chemotherapy. [Tzu Chi Med J 2007;19(3):173–178]
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1. Introduction
Blastic NK-cell lymphoma is an aggressive malignancy 
and often has cutaneous lesions at initial manifesta-
tion. About half of patients have nodal or bone mar-
row involvement at presentation [1–3]. Most patients 
with only skin involvement at the beginning rapidly 
develop bone marrow, peripheral blood, and lymph 
node involvement. Histologically, blastic NK-cell lym-
phoma shows monocytic infiltrates of medium sized 
cells resembling lymphoblasts or myeloblasts with 
CD56 immunoreactivity [1,4–6]. There are about 150 
well-documented cases of blastic NK-cell lymphoma 
in the literature with several large series representing 
more than half of published cases [2,6–8]. Suzuki et al 
reported 47 patients with blastic NK-cell lymphoma 
collected from a nationwide survey in a Japanese NK-
cell tumor study group from 1994–1998 [8]. Petrella 
et al showed a series of 30 cases from a French study 
group on cutaneous lymphoma [6]. Bekkenk et al from 
the Netherlands reported an analysis of 11 new cases 
and reviewed 52 cases from the literature [2]. Massone 
et al from Austria reported 12 cases of blastic NK-
cell lymphoma in their series [7]. Blastic NK-cell lym-
phoma represented 0.7% of the primary cutaneous 
lymphoma registered by the French Study Group 
on Cutaneous Lymphomas [6]. Due to the rarity of 
this entity, we herein report a case of blastic NK-cell 
lymphoma.
2. Case report
A 19-year-old man presented with many erythema-
tous nodules and plaques on the face, trunk and 
extremities. The nodules and plaques developed rap-
idly over 1 month. The patient did not complain of 
any systemic symptoms. Physical examination did 
not reveal any abnormality. Dermatological examina-
tion showed many bean-sized infiltrative, erythema-
tous, non-tender nodules or plaques located on the 
face, neck, trunk, and extremities (Fig. 1). A skin 
biopsy specimen taken from the back showed infil-
tration of medium-sized blastic cells in the dermis 
and subcutis. Monocytic infiltrates of medium-sized 
blasts made a diagnosis of large tumor cells (i.e. dif-
fuse large B-cell lymphoma) or predominantly small 
cells (i.e. small lymphocytic lymphoma) unlikely in 
this case. The neoplastic cells were characterized by 
dispersed nuclear chromatin, somewhat irregular 
nuclear membrane and scant cytoplasm (Fig. 2). No 
epidermotropism, angiodestruction, or angiocentric 
pattern was found. Immunohistochemical studies 
showed that the tumor cells were positive for CD56, 
CD123, CD43, and terminal deoxynucleotidyl trans-
ferase (TdT). The tumor cells were negative for CD3, 
CD20, CD30, CD79a, and myeloperoxidase. In situ 
hybridization did not detect Epstein-Barr virus encoded 
RNA (EBER). A bone marrow biopsy showed hypocel-
lular marrow with an M/E ratio of 3:2. Aggregation of 
blasts was easily demonstrated in bone marrow sec-
tions. The blasts had a pleomorphic appearance from 
myeloblasts or lymphoblasts. Neoplastic cells were 
positive for CD56 and CD123 (Fig. 3). Flow cyto-
metric analysis found predominantly CD56 positive 
blasts in the bone marrow. Laboratory investigations, 
including complete cell counts, liver enzymes, kidney 
function and electrolyte levels, were all within normal 
limits. A whole body computed tomography (CT) scan 
also found no abnormalities. The patient was diag-
nosed with blastic NK-cell lymphoma with bone mar-
row involvement and underwent L-asparaginase-based 
chemotherapy (L-asparaginase, 10,000 IU [6000 IU/
m2] subcutaneous on days 1–7; cyclophosphamide, 
600 mg intravenous infusion for 1 hour on day 1–2; 
etoposide [VP16], 100 mg intravenous infusion on 
days 1–4). The skin lesions cleared after the first 
course. However, elevated liver function test (alanine 
aminotransferase, 383 U/L; reference, 0–35 U/L) post-
poned subsequent treatment. After liver function 
returned to normal, a second course of chemother-
apy was delivered 6 weeks after the first course with 
minor side effects of nausea and vomiting. The duration 
of follow-up was 2 months. This patient will receive 
allogeneic or autologous stem cell transplantation.
3. Discussion
The World Health Organization (WHO) classification 
recognizes the following NK-cell malignancies: aggres-
sive NK-cell leukemia; extranodal NK/T-cell leuke-
mia, nasal type; and blastic NK-cell lymphoma [9]. 
The origin of the neoplastic cells in blastic NK-cell 
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Fig. 1 — (A) Many bean-sized, erythematous, infiltrative plaques located on the back. (B) Confluent erythematous 
plaques and nodules located on the right cheek.






Fig. 2 — (A) Diffuse non-epidermotropic infiltration of medium-sized blast cells in the dermis (hematoxylin & eosin 
[H&E], 40´). (B) The tumor cells have dispersed nuclear chromatin, an irregular nuclear membrane, and scant cyto-
plasm (H&E, 200´). Tumor cells are positive for: (C) CD56 (100´); (D) CD43 (100´); (E) CD123 (100´); and (F) terminal 
deoxynucleotidyl transferase (100´).
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lymphoma has not yet been ascertained. Based on 
the blastic cytologic appearance and CD56 expres-
sion, an NK-precursor origin was initially suggested 
[9]. Simultaneous expression of stem cell markers 
and the NK-cell receptor complex CD94/NKG2 also 
favored origin from an NK-cell precursor [10]. But 
recent studies found evidence suggesting early plas-
macytoid type 2 dendritic cell (DC2) origins [11,12].
Clinically, blastic NK-cell lymphoma commonly 
presents in the skin with solitary or multiple nodules 
or tumors with or without concurrent extracutane-
ous localization [4]. About half of patients have bone 
marrow involvement at presentation [2,3,13]. The 
average age at presentation ranged from 53 to 74.3 
years in several reported series [2,7,8].
Histologically, blastic NK-cell lymphoma is char-
acterized by an infiltrate of medium-sized neoplas-
tic cells with blastoid morphology. The epidermis 
is not involved as a rule, whereas involvement of 
the subcutaneous tissue is common. The neoplastic 
cells have finely dispersed chromatin, and absent or 
indistinct nucleoli resembling lymphoblasts or myelo-
blasts [2,3,13]. A special immunophenotypic feature 
of blastic NK-cell lymphoma is positivity for CD56 
antigen. The tumor cells usually also express CD4 
and CD43 [8]. Expression of CD2, CD7, cytotoxic 
molecules, TdT, CD34 and CD68 varies. Other T cell 
markers and myelomonocytic markers are negative 
[14]. Since lymphoblastic and myeloblastic neoplasms 
can also be positive for CD56, stains for CD3 and 
myeloperoxidase should always be performed in order 
to exclude these entities [3]. The cells express CD123, 
which supports a relationship with plasmacytoid den-
dritic cells [15]. Recent studies demonstrated that 
blastic NK-cell lymphoma expresses markers typical 
of plasmacytoid dendritic cells, in particular the IL-3R 
alpha chain (CD123) [15].
The differential diagnosis includes other CD56+ 
lymphomas with cutaneous involvement [2]. These 
include extranodal NK/T-cell lymphoma, nasal type; 
CD56+ myeloid leukemia; and cutaneous Cd30+ 
lymphoproliferation with CD56 expression [2,3]. 
Extra nodal NK/T-cell lymphoma is nearly always 
an EBV+ lymphoma. The skin is the second most 
common site of involvement after the nasal cavity/
nasopharynx [3,9,13]. Prominent angiocentricity and 
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Fig. 3 — (A) Medium-sized blasts infiltrating the bone 
marrow (hematoxylin & eosin, 100´). The neoplastic cells 
are positive for: (B) CD56 (200´); and (C) CD123 (200´).
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angiodestruction are often accompanied by exten -
sive necrosis. The neoplastic cells of extranodal NK/
T-cell lymphoma express CD56, cytoplasmic CD3, 
and cytotoxic proteins, but lack surface CD3 [2,3]. In 
this case, EBV was not detected by in situ hybridiza -
tion. Because the tumor cells were negative for EBV, 
the possibility of extranodal NK/T-cell lymphoma, 
nasal type, was excluded. NK-cell lymphoma and 
CD56+ myeloid leukemia have great similarity in 
clinical, histological and immunohistological pres-
entations [2]. However, our case had negative stain-
ing for the myeloid marker myeloperoxidase and 
this excluded the possibility of CD56+ myeloid 
leukemia.
There is no standard treatment for advanced 
blastic NK-cell lymphoma [3,13]. Initial treatment con-
sists of multiagent chemotherapy in the majority of 
patients, and most patients receive CHOP (cyclophos-
phamide, doxorubicin, vincristine, prednisone) or a 
CHOP-like regimen [2,8]. Response to combination 
chemotherapy, such as CHOP, is minimal or transient 
and early progression is common [2,8]. Radiation 
therapy is effective for localized disease only. A 
CHOP-like regimen and radiotherapy are inadequate 
therapies for this type of neoplasm. More aggressive 
therapies direc ted to allogeneic stem cell transplan-
tation are probably superior. Young patients treated 
with aggressive regimens used in acute leukemia have 
a better prognosis than patients treated with CHOP-
like regimens [16]. Long-term remission of blastic 
NK/T-cell lymphoma was reported after autologous 
peri pheral blood stem cell transplantation [17]. 
Significant survival benefits were found in patients 
with blastic NK-cell lymphoma who underwent hemat-
opoietic stem cell transplantation [18]. Therefore, 
allogeneic or autologous stem cell transplantation is 
a promising treatment strategy and should be rec-
ommended to the patient. Rapid clearance of skin 
lesions represents responsiveness of blastic NK-cell 
lymphoma to L-asparaginase-based chemotherapy. 
The rationale is based on reports that L-asparaginase 
is effective in the treatment of NK/T-cell lymphoma 
[19–22]. Childhood blastic NK-cell leukemia was also 
reportedly successfully treated with L-asparaginase 
[23]. L-asparaginase could induce selective apop-
tosis of natural killer-cell tumors [24]. Recently, an 
L-asparaginase-based regimen was reported to be a 
promising new sal vage chemotherapeutic regimen in 
CHOP failures and improved treatment outcome in 
midline NK/T-cell lymphoma, nasal type [25].
The prognosis of blastic NK-cell lymphoma is poor, 
with a median survival of 14 months and 2- and 5- 
year overall survivals of 33% and 6%, respectively 
[2]. Patients with only skin involvement tend to have 
longer survival than those with extracutaneous dis-
ease [2,8]. Young age (≤ 40 years), TdT expression of 
> 50% neoplastic cells, and cutaneous involvement 
only were independent prognostic variables for a 
better prognosis [2,8].
In Taiwan, Lin et al reported a 35-year-old man 
diagnosed with blastic NK-cell lymphoma with skin 
and bone marrow involvement [26]. He initially pre-
sented with erythematous and purpuric plaques on 
the face and trunk. Blastic-like lymphoid cells were 
found infiltrating the dermis and subcutis in a biopsy 
specimen. The tumor cells were immunoreactive to 
CD56 but not other T-cell, B-cell, or myeloid mark-
ers or EBV. The patient did not attain remission and 
skin lesions persisted despite four courses of CHOP. 
The clinical, histological and immunohistological char-
acteristics of our present case are similar to that 
reported by Lin et al [26]. However, our patient was 
younger and more responsive to the L-asparaginase-
based chemotherapy.
In conclusion, we reported a rare case of blastic 
NK-cell lymphoma with bone marrow involvement. 
Accurate pathological diagnosis of this neoplasm is 
essential for prognosis and treatment. Although the 
patient responded to initial chemotherapy, hemat-
opoietic stem cell transplantation may be needed to 
prolong his survival.
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